The CARD17 antibody targets the Caspase Recruitment Domain (CARD)-containing protein 17. a member of the CARD protein family involved in apoptosis, inflammation, and immune regulation. CARD proteins typically function as adaptors in signaling pathways, mediating interactions between caspases, kinases, or other regulatory molecules. CARD17. though less characterized than other CARD family members (e.g., CARD11. CARD14), is proposed to modulate NF-κB and caspase-dependent pathways, potentially acting as an inhibitor or activator depending on cellular context. Its expression has been linked to immune cells and certain cancers, suggesting roles in tumorigenesis or immune response modulation. Antibodies against CARD17 are primarily used in research to detect protein expression, study its interactions, and elucidate its biological functions. Commercial CARD17 antibodies are often validated for applications like Western blotting, immunohistochemistry, or immunofluorescence. However, its precise physiological and pathological roles remain under investigation, partly due to limited studies and potential functional redundancy within the CARD family. Developing specific, high-affinity CARD17 antibodies remains critical for clarifying its role in cellular signaling and disease mechanisms.